These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2890501)

  • 21. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months.
    Birkeland KI; Furuseth K; Melander A; Mowinckel P; Vaaler S
    Diabetes Care; 1994 Jan; 17(1):45-9. PubMed ID: 8112188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of sensitivity to sulfonylurea after strict glycaemic control with insulin in non-obese type 2 diabetic subjects.
    Torella R; Salvatore T; Cozzolino D; Giunta R; Quatraro A; Giugliano D
    Diabete Metab; 1991; 17(5):443-7. PubMed ID: 1752344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
    Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function.
    Di Mauro M; Papalia G; Le Moli R; Nativo B; Nicoletti F; Lunetta M
    Diabetes Res Clin Pract; 2001 Jan; 51(1):45-50. PubMed ID: 11137181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone.
    Groop L; Harno K; Nikkilä EA; Pelkonen R; Tolppanen EM
    Acta Med Scand; 1985; 217(1):33-9. PubMed ID: 3919531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy for NIDDM with biosynthetic human insulin and glyburide.
    Mezitis NH; Heshka S; Saitas V; Bailey TS; Costa R; Pi-Sunyer FX
    Diabetes Care; 1992 Feb; 15(2):265-9. PubMed ID: 1547684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy--results of a one-year double blind study].
    Lundershausen R; Orban S; Pissarek D; Panzram G
    Wien Klin Wochenschr; 1987 Sep; 99(17):603-8. PubMed ID: 3118579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of improvement in glucose metabolism after chronic glyburide therapy.
    Simonson DC; Ferrannini E; Bevilacqua S; Smith D; Barrett E; Carlson R; DeFronzo RA
    Diabetes; 1984 Sep; 33(9):838-45. PubMed ID: 6432610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fenfluramine increases insulin action in patients with NIDDM.
    Pestell RG; Crock PA; Ward GM; Alford FP; Best JD
    Diabetes Care; 1989 Apr; 12(4):252-8. PubMed ID: 2495916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone.
    Lardinois CK; Liu GC; Reaven GM
    Arch Intern Med; 1985 Jun; 145(6):1028-32. PubMed ID: 3923961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of glyburide on metabolic control and insulin binding in insulin-dependent diabetes mellitus.
    Goldman J; Tamayo RC; Whitehouse FW; Kahkonen DM
    Diabetes Care; 1984; 7 Suppl 1():106-12. PubMed ID: 6428843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
    Damsbo P; Clauson P; Marbury TC; Windfeld K
    Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracellular glucose metabolism after long term metabolic control with glyburide: improved glucose oxidation with unchanged glycogen synthase activity.
    Suh KI; Murata C; Song YM; Joyce M; Gumbiner B; Ditzler TM; Henry RR
    J Clin Endocrinol Metab; 1993 Aug; 77(2):464-70. PubMed ID: 8345053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects.
    Riddle MC; Hart JS; Bouma DJ; Phillipson BE; Youker G
    Diabetes Care; 1989 Oct; 12(9):623-9. PubMed ID: 2507265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
    Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
    Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of combined insulin-sulfonylurea therapy in type II patients.
    Lewitt MS; Yu VK; Rennie GC; Carter JN; Marel GM; Yue DK; Hooper MJ
    Diabetes Care; 1989 Jun; 12(6):379-83. PubMed ID: 2499443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
    Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function.
    Verdonk CA; Rizza RA; Nelson RL; Go VL; Gerich JE; Service FJ
    J Clin Invest; 1980 May; 65(5):1119-25. PubMed ID: 6988457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.